** Shares of Immuron IMC.AX rise as much as 104.6% to
A$0.135, posting their biggest intraday gain since July 21, 2020
** Stock hits its highest level since Feb 8, 2022
** Drugmaker says reports positive results from the clinical
trials for its flagship diarhhea drug, Travelan
** Says results support Travelan's progress to late-stage
clinical trials in the U.S.
** Adds co is proceeding to Phase 3 trial registration
strategy with U.S. FDA
** About 19.7 mln shares change hands, compared with the
30-day average volume of 111,932
** Stock down 14.3% YTD as of last close
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com;))